ASCO GU 2023: Efficacy and Safety of Darolutamide in Combination with ADT and Docetaxel by Disease Volume and Disease Risk in the Phase 3 ARASENS Study urotoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from urotoday.com Daily Mail and Mail on Sunday newspapers.
Vaisala announced its latest innovations in WindCube Scan. New features include a more robust exterior, new scanning head, and enhanced laser design to
Vaisala Press release October 10, 2022 Vaisala redefines wind measurement with enhanced WindCube Scan suite to optimize operations and mitigate. | October 10, 2022
Adding capecitabine to a chemotherapy regimen that contained docetaxel, epirubicin, and cyclophosphamide prolonged the survival of patients with early breast cancer, according to long-term results from the Heikki Joensuu, MD, of Helsinki University Hospital, and colleagues looked at 15-year overall survival data from the trial, in which 1,500 patients with early breast cancer were randomized to one of two treatments:Three cycles of docetaxel plus capecitabine followed by three cycles of cyclophosphamide, epirubicin, and capecitabineThree cycles of docetaxel followed by three cycles of cyclophosphamide, epirubicin, and fluorouracil The analysis, published in the , showed a 15-year survival rate of 77.6% in the patients who received capecitabine compared with 73.3% in the other treatment group (HR 0.81, 95% CI 0.66-0.99, P=0.037).
ASCO GU 2022: Long-Term Safety of Darolutamide in Patients with Metastatic Castration-Resistant Prostate Cancer urotoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from urotoday.com Daily Mail and Mail on Sunday newspapers.